Cell Therapeutics Appoints New Chief Medical Officer MarketWatch (press release) ... CTI's ongoing randomized controlled phase 3 clinical trial, which compares Pixuvri-rituximab to gemcitabine-rituximab in patients who have relapsed after one ... |
Cell Therapeutics Appoints New Chief Medical Officer MarketWatch (press release) ... CTI's ongoing randomized controlled phase 3 clinical trial, which compares Pixuvri-rituximab to gemcitabine-rituximab in patients who have relapsed after one ... |